Fintel reports that on February 24, 2025, Guggenheim initiated coverage of Compass Therapeutics (NasdaqCM:CMPX) with a Buy recommendation. Analyst Price Forecast Suggests 266.05% Upside As of February ...
Zacks Research increased their Q3 2025 earnings per share (EPS) estimates for Microsoft in a research report issued on Wednesday, February 19th. Zacks Research analyst V. Sawalka now anticipates that ...
J.P. Morgan has upgraded Amneal Pharmaceuticals, Inc (NASDAQ:AMRX), noting the company’s generics business is increasingly ...
Principal Financial Group Inc. increased its stake in shares of Commvault Systems, Inc. (NASDAQ:CVLT – Free Report) by 1.1% ...
Eltura Capital Management, LLC ("Eltura" and the "Firm"), an alternative investment manager specializing in asset-based finance and structured credit opportunities, today announces that it has secured ...
LifeSci Capital analyst Jimmy Shan initiated coverage on Tourmaline Bio, Inc. TRML with an Outperform rating and announced a ...
Johnson & Johnson’s stock rose 1.1% on Thursday, reaching $159.56. Trading volume dropped significantly, with 1.7 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback